Candel Therapeutics Ownership | Who Owns Candel Therapeutics?

Candel Therapeutics Ownership Summary

Candel Therapeutics is owned by 81.91% institutional investors, 15.79% insiders, and 2.30% retail investors. Fmr is the largest institutional shareholder, holding 20.75% of CADL shares. Fidelity Select Biotechnology is the top mutual fund, with 8.07% of its assets in Candel Therapeutics shares.

CADL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Candel Therapeutics	81.91%	15.79%	2.30%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	10.99M	20.75%	$53.84M
Rtw investments, lp	6.42M	12.13%	$31.47M
Northpond ventures	1.94M	6.63%	$12.00M
Acorn capital advisors	3.50M	6.61%	$17.21M
Blackrock funding, inc. /de	3.11M	5.87%	$15.23M
Saturn v capital management	2.90M	5.47%	$14.19M
Portolan capital management	2.89M	5.47%	$14.18M
Vanguard group	2.31M	4.20%	$13.02M
Blackrock	823.07K	2.82%	$5.10M
Vestal point capital, lp	1.13M	2.12%	$5.51M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Northpond ventures	1.94M	21.71%	$12.00M
Acorn capital advisors	3.50M	4.89%	$17.21M
Saturn v capital management	2.90M	2.57%	$14.19M
Heights capital management	775.00K	1.06%	$3.80M
Halter ferguson financial	904.05K	0.97%	$4.43M
Portolan capital management	2.89M	0.75%	$14.18M
Sands capital ventures	405.84K	0.47%	$1.99M
Rtw investments, lp	6.42M	0.31%	$31.47M
Stonepine capital management	102.50K	0.20%	$502.25K
Alphacentric advisors	36.31K	0.18%	$177.93K

Top Buyers

Holder	Shares	% Assets	Change
Rtw investments, lp	6.42M	0.31%	6.42M
Saturn v capital management	2.90M	2.57%	2.90M
Fmr	10.99M	0.00%	2.75M
Portolan capital management	2.89M	0.75%	1.20M
Vestal point capital, lp	1.13M	0.15%	1.13M

Top Sellers

Holder	Shares	% Assets	Change
Braidwell lp	-	-	-1.60M
Baker bros. advisors lp	-	-	-355.11K
Franklin resources	-	-	-211.01K
Citadel advisors	72.67K	0.00%	-153.69K
Marshall wace, llp	-	-	-103.85K

New Positions

Holder	Shares	% Assets	Change	Value
Rtw investments, lp	6.42M	0.31%	6.42M	$31.47M
Saturn v capital management	2.90M	2.57%	2.90M	$14.19M
Vestal point capital, lp	1.13M	0.15%	1.13M	$5.51M
Heights capital management	775.00K	1.06%	775.00K	$3.80M
Vanguard fiduciary trust	280.45K	0.00%	280.45K	$1.37M

Sold Out

Holder	Change
Qube research	-1.00
National bank of canada /fi/	-3.00
True wealth design	-8.00
Signaturefd	-39.00
Srs capital advisors	-54.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	114	29.55%	43,379,447	83.55%	81	4.42%	81	76.09%	18	5.88%
Dec 31, 2025	36	-57.65%	7,862,320	-65.29%	14	0.74%	20	-50.00%	5	-80.77%
Sep 30, 2025	36	-56.63%	7,158,075	-68.93%	13	0.26%	20	-64.91%	9	-40.00%
Jun 30, 2025	83	-5.68%	23,028,788	8.68%	72	4.13%	56	-11.11%	16	33.33%
Mar 31, 2025	88	12.82%	21,199,863	18.25%	41	1.34%	63	16.67%	12	50.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Select Biotechnology	5.91M	8.07%	-
Fidelity Growth Compy Commingled Pl S	2.36M	3.22%	3.27K
Vanguard Total Stock Mkt Idx Inv	1.97M	2.69%	-
Fidelity Growth Company Fund	1.74M	2.37%	-
Strategic Advisers U.S. Total Stock	1.68M	2.29%	-
iShares Russell 2000 ETF	1.07M	1.46%	9.02K
Fidelity Growth Company K6	501.38K	0.68%	-3.27K
Fidelity Series Growth Company	477.84K	0.65%	-
Vanguard Institutional Extnd Mkt Idx Tr	439.41K	0.60%	-
Fidelity Small Cap Index	429.00K	0.59%	3.70K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 23, 2026	Manning Paul B	-	Buy	$3.00M
Jul 28, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$6.54K
Jun 30, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$3.94K
Mar 18, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$397.00K
Mar 18, 2025	Barone Francesca	Chief Scientific Officer	Sell	$281.67K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	1	-
2025 Q3	-	1
2025 Q2	-	1
2025 Q1	-	16
2024 Q4	2	10

CADL Ownership FAQ

Who Owns Candel Therapeutics?

Candel Therapeutics shareholders are primarily institutional investors at 81.91%, followed by 15.79% insiders and 2.30% retail investors. The average institutional ownership in Candel Therapeutics's industry, Biotech Stocks , is 35.75%, which Candel Therapeutics exceeds.

Who owns the most shares of Candel Therapeutics?

Candel Therapeutics’s largest shareholders are Fmr (10.99M shares, 20.75%), Rtw investments, lp (6.42M shares, 12.13%), and Northpond ventures (1.94M shares, 6.63%). Together, they hold 39.50% of Candel Therapeutics’s total shares outstanding.

Does Blackrock own Candel Therapeutics?

Yes, BlackRock owns 2.82% of Candel Therapeutics, totaling 823.07K shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.1M$. In the last quarter, BlackRock increased its holdings by 775.49K shares, a 1629.87% change.

Who is Candel Therapeutics’s biggest shareholder by percentage of total assets invested?

Northpond ventures is Candel Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.71% of its assets in 1.94M Candel Therapeutics shares, valued at 12M$.

Who is the top mutual fund holder of Candel Therapeutics shares?

Fidelity Select Biotechnology is the top mutual fund holder of Candel Therapeutics shares, with 8.07% of its total shares outstanding invested in 5.91M Candel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools